Financial Markets collage Northcote Internet Logo
transparent spacer
transparent spacer
 >   > 
transparent spacer
 
curve on page transparent spacer
Northcote Internet Ltd provide Investor Relations Webcasting. Click Here
 
transparent spacer transparent spacer transparent spacer transparent spacer
transparent spacer Home menu end curves
Newsletter
transparent spacer
transparent spacer About Us menu end curves
transparent spacer
transparent spacer Donations menu end curves
transparent spacer
transparent spacer Registrars menu end curves
transparent spacer
transparent spacer Spread Betting menu end curves
transparent spacer
transparent spacer Submit links menu end curves
transparent spacer
transparent spacer transparent spacer
transparent spacer transparent spacer transparent spacer
transparent spacer
transparent spacer
navigation curves Home navigation curves navigation curves By Index navigation curves navigation curves By Sector navigation curves navigation curves Alphabetically navigation curves navigation curves Search navigation curves navigation curves My Portfolio navigation curves
 >  > 
 
Follow northcote_b on Twitter
AstraZeneca
transparent spacer
transparent spacer
transparent spacer
Company Information
Address: Level 9 2 Kingdom Street
London
W2 6BD
Index: To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.
Tel: +44 (0)20 7604 8000 Sector:
Fax: +44 (0)20 7604 8270
E-Mail: IR@astrazeneca.com Epic:
Secretary: Adrian Kemp    
Registrar: Equiniti Ltd Updated: 9/02/2015

News from RSS Feed

Thu, 30 Jul 2015 06:58:00 +0100

AstraZeneca PLC H1 2015 results

“We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas."

Company Overview

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives

 
Annual Reports
Description Report Date Published Current  
bullet point Annual Report 2014 in PDF 31/12/2014 5/02/2015 Yes  
bullet point Annual Report 2013 in PDF 31/12/2013 6/02/2014 No  
bullet point Annual Report 2012 in PDF 31/12/2012 31/01/2013 No  
bullet point Annual Report 2011 in PDF 31/12/2011 2/02/2012 No  
bullet point Annual Report 2010 in PDF 31/12/2010 27/01/2011 No  
bullet point Annual Report 2009 in PDF 31/12/2009 28/01/2010 No  
bullet point Annual Report 2008 in PDF 31/12/2008 29/01/2009 No  
bullet point Annual Report 2007 in PDF 31/12/2007 31/01/2008 No  
 
Interim Reports
Description Report Date Published Current  
bullet point Interim Results 2014 in PDF 30/06/2014 31/07/2014 Yes  
bullet point Interim Results 2013 in PDF 30/06/2013 1/08/2013 No  
bullet point Interim Results 2012 in PDF 30/06/2012 26/07/2012 No  
 
Other Links
Description
bullet point Home
bullet point Site Map
bullet point Investor Relations
bullet point Events Calendar
bullet point Results Index
bullet point Press Releases
bullet point Presentations
bullet point Contacts
bullet point RSS News Feed
       
Dividend History
Type Payment Date Dividend
Interim 15/09/2014 53.1 p
Interim 24/03/2014 116.8 p
Interim 16/09/2013 59.2 p
Interim 18/03/2013 120.5 p
Interim 10/09/2012 58.1 p
Interim 19/03/2012 123.6 p
Interim 12/09/2011 51.9 p
Interim 14/03/2011 116.7 p
Interim 13/09/2010 44.9 p
Interim 15/03/2010 105.4 p
Interim 14/09/2009 0.59 c USD
Interim 14/09/2009 27.8 p
Interim 14/09/2009 36 p
Interim 16/03/2009 104.8 p
Interim 15/09/2008 27.8 p
Interim 17/03/2008 67.7 p
Interim 17/09/2007 25.3 p
Interim 19/03/2007 63 p
Interim 18/09/2006 26.6 p
Interim 20/03/2006 51.8 p
Interim 19/09/2005 21.9 p
Interim 21/03/2005 34.3 p
Interim 20/09/2004 16 p
Interim 6/04/2004 29.4 p
Interim 6/10/2003 15.9 p
Interim 7/04/2003 28.5 p
Interim 7/10/2002 14.7 p
Interim 8/04/2002 33.2 p
Interim 5/10/2001 16.1 p
Interim 9/04/2001 32.1 p
Interim 23/10/2000 15.3 p
Interim 17/04/2000 29.1 p
Interim 25/10/1999 14.2 p

News from RSS Feed

Thu, 30 Jul 2015 06:58:00 +0100

AstraZeneca PLC H1 2015 results

“We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas."
Mon, 27 Jul 2015 07:00:00 +0100

AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa

AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine.
Wed, 22 Jul 2015 06:24:56 +0100

AstraZeneca provides update on selumetinib in uveal melanoma

AstraZeneca provides update on selumetinib in uveal melanoma
Fri, 17 Jul 2015 06:41:13 +0100

AstraZeneca completes agreement with Tillotts Pharma for Entocort

AstraZeneca today announced that it has completed its agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort ® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis.
Thu, 16 Jul 2015 06:13:50 +0100

AstraZeneca enters option agreement with Kyowa Hakko Kirin for commercialisation of benralizumab in Japan

AstraZeneca today announced that it has entered an agreement with Kyowa Hakko Kirin Co. Ltd. (Kyowa Hakko Kirin) for an exclusive option to commercialise benralizumab for asthma and chronic obstructive pulmonary disease (COPD) in Japan.
Mon, 13 Jul 2015 20:26:47 +0100

IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved IRESSA (gefitinib) tablets, 250mg once daily, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.
Thu, 9 Jul 2015 07:30:00 +0100

AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma for Entocort

AstraZeneca announced today that it has entered into an agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis. Entocort is currently available in over 40 countries, with total product sales of $53 million outside the US in 2014. A regulatory submission for Entocort in Japan is anticipated in the coming months.
Tue, 16 Jun 2015 07:00:00 +0100

AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT

AstraZeneca today announced that Pam P. Cheng has joined the Company as Executive Vice President, Operations and IT. Pam will succeed David Smith, who is retiring after nearly ten years with AstraZeneca.
Thu, 11 Jun 2015 08:00:00 +0100

AstraZeneca reveals findings of archaeological dig as build gets underway at Cambridge Biomedical Campus

AstraZeneca today announced the findings of archaeological excavations on the Cambridge Biomedical Campus, which will be home to the Company’s new, purpose-built global R&D centre and corporate headquarters from the end of 2016.
Mon, 8 Jun 2015 11:55:57 +0100

New real-world data analysis finds no evidence of increased risk of hospitalisation for heart failure with saxagliptin compared with sitagliptin

AstraZeneca today announced results from an observational, retrospective study which found no evidence of increased risk of hospitalisation for heart failure (hHF) with saxagliptin, compared with sitagliptin, both of which are dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes. A similar finding was obtained when comparing the overall DPP-4 class to sulfonylureas. The analysis included patients with and without prior cardiovascular disease (CVD), and among those patients without prior cardiovascular disease (CVD), DPP-4 treatment was associated with statistically significant lower risk for hHF compared to treatment with sulfonylureas.
To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.


transparent spacer